MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Glycated alpha-synuclein and it emerging role in early onset of Parkinson’s disease

S. Chatterjee, H. Thakkar, A. Khairnar, R. Shah (Gandhinagar, India)

Meeting: 2023 International Congress

Abstract Number: 1459

Keywords: Alpha-synuclein, Dopaminergic neurons, Oxidative stress

Category: Parkinson's Disease: Molecular Mechanisms of Disease

Objective: To elucidate, the molecular mechanism underlying glycated α-Syn mediated dopaminergic (DAergic) neurodegeneration in the substantia nigra (SN) via the AGE/RAGE signaling pathway.

Background: Intracytoplasmic inclusion of Lewy bodies, primarily containing α-Syn, is a pathological hallmark for Parkinson’s disease. While the glycation with methylglyoxal results in α-Syn misfolded and aggregation has been studied, the effects of glycated α-Syn and how it affects the α-Syn aggregation at the early onset of Parkinson’s disease have not been investigated.

Method: Through rDNA technology, we first purified and characterized recombinant human α-Syn (rh α-Syn). We established that glycation (an unavoidable age-associated post-translational modification) with d-ribose and characterized it by LC-MS/MS, transmission electron microscopy (TEM), MALDI TOF-MS and atomic force microscopy (AFM) analysis. Furthermore, post-translational toxicity of α-Syn was investigated in wild-type ICR mice by intranigral injection of a single dosage of glycated α-Syn (2µg/µl). Behavioral assessments were done every week. To check glycated α-Syn induced neurodegeneration, age-dependent sensitivity of DAergic neurons, and contribution in AGE/RAGE signaling cascade, immunohistochemical analysis were performed at different time points (28, and 56-day post-surgery).

Results: After rh α-Syn was successfully purified, we found the mass increment (~2kDa) of glycated α-Syn by using MALDI TOF-MS. This was supported by the use of TEM and AFM to find alterations in the internal structure of this protein. At 56-days post-surgery, immunofluorescence labeling revealed an upregulation of RAGE resulting in significant loss of TH+ neurons in substantia nigra pars compacta (SNc). Iba1 and GFAP expression were elevated in order to activate the inflammatory cascade caused by RAGE. Additionally, we found that glycated α-Syn increased malondialdehyde levels resulting in ROS production, which may have contributed to the upregulation of caspases which lead to the age-dependent sensitivity of DAergic neurons to degeneration by activating RAGE.

Conclusion: We uncovered that d-ribose-derived glycation played a significant role in the exacerbation or anticipation of early onset of PD-like symptoms, indicating that anti-glycation or anti-diabetic agents may be effective in treating Parkinson’s disease.

To cite this abstract in AMA style:

S. Chatterjee, H. Thakkar, A. Khairnar, R. Shah. Glycated alpha-synuclein and it emerging role in early onset of Parkinson’s disease [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/glycated-alpha-synuclein-and-it-emerging-role-in-early-onset-of-parkinsons-disease/. Accessed October 4, 2026.
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to 2023 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/glycated-alpha-synuclein-and-it-emerging-role-in-early-onset-of-parkinsons-disease/

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley